Selective unresponsiveness to beta cell autoantigens after induction immunosuppression in pancreas transplantation with anti-interleukin-2 receptor antibody versus anti-thymocyte globulin

Clinical and Experimental Immunology

Volumn 149, Issue 1, 2007, Pages 56-62

  Van De Linde, P ^a   Boog, P J M Vd ^a   Tysma, O M H ^a   Elliott, J F ^b   Roelen, D L ^a   Claas, F H J ^a   De Fijter, J W ^a   Roep, B O ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Antibodies; Diabetes mellitus; Immunotherapy; Pancreas; Transplantation

Indexed keywords

AUTOANTIGEN; BACTERIAL ANTIGEN; CYCLOSPORIN A; DACLIZUMAB; GLUTAMATE DECARBOXYLASE 65; INSULIN; INTERLEUKIN 2 RECEPTOR ANTIBODY; METHYLPREDNISOLONE SODIUM SUCCINATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; PROTEIN P53; THYMOCYTE ANTIBODY; TUBERCULIN; TUMOR ANTIGEN; VIRUS ANTIGEN;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; AUTOIMMUNITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; HAEMOPHILUS INFLUENZAE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LYMPHOCYTE ACTIVATION; MALE; PANCREAS GRAFT REJECTION; PANCREAS TRANSPLANTATION; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; STATISTICAL SIGNIFICANCE; T LYMPHOCYTE; VIRUS IMMUNITY;

ADULT; ANTIBODIES, MONOCLONAL; ANTILYMPHOCYTE SERUM; AUTOANTIGENS; CD4 LYMPHOCYTE COUNT; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 1; FEMALE; GRAFT REJECTION; HUMANS; IMMUNE TOLERANCE; IMMUNOGLOBULIN G; IMMUNOLOGIC MEMORY; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; INSULIN-SECRETING CELLS; INTERLEUKIN-2; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PANCREAS TRANSPLANTATION; RECEPTORS, INTERLEUKIN-2; RECOMBINANT PROTEINS;

EID: 34250160238     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2007.03400.x     Document Type: Article

References (39)

1. Sibley RK, Sutherland DE, Goetz F, Michael AF. Recurrent diabetes mellitus in the pancreas iso- and allograft. A light and electron microscopic and immunohistochemical analysis of four cases. Lab Invest 1985 53 : 132 44.
2. Roep BO, Arden SD, de Vries RR, Hutton JC. T-cell clones from a type-1 diabetes patient respond to insulin secretory granule proteins. Nature 1990 345 : 632 4.
3. Roep BO, Kallan AA, Duinkerken G et al. T-cell reactivity to beta-cell membrane antigens associated with beta-cell destruction in IDDM. Diabetes 1995 44 : 278 83.
4. Roep BO, Stobbe I, Duinkerken G et al. Auto- and alloimmune reactivity to human islet allografts transplanted into type 1 diabetic patients. Diabetes 1999 48 : 484 90.
5. Roep BO. The role of T-cells in the pathogenesis of Type 1 diabetes: from cause to cure. Diabetologia 2003 46 : 305 21.
6. Lampeter EF, Homberg M, Quabeck K et al. Transfer of insulin-dependent diabetes between HLA-identical siblings by bone marrow transplantation. Lancet 1993 341 : 1243 4.
7. Brooks-Worrell BM, Peterson KP, Peterson CM, Palmer JP, Jovanovic L. Peripheral blood mononuclear cell responses from type 1 diabetic patients and subjects at-risk for type 1 diabetes to human fetal pancreatic tissue proteins. Transplantation 2000 69 : 1907 12.
8. Bougneres PF, Carel JC, Castano L et al. Factors associated with early remission of type I diabetes in children treated with cyclosporine1. N Engl J Med 1988 318 : 663 70.
9. Sutherland DE, Gruessner RW, Dunn DL et al. Lessons learned from more than 1,000 pancreas transplants at a single institution. Ann Surg 2001 233 : 463 501.
10. Sutherland DE, Gruessner RW, Gruessner AC. Pancreas transplantation for treatment of diabetes mellitus. World J Surg 2001 25 : 487 96.
11. Smets YF, Westendorp RG, van der Pijl JW et al. Effect of simultaneous pancreas-kidney transplantation on mortality of patients with type-1 diabetes mellitus and end-stage renal failure. Lancet 1999 353 : 1915 9.
12. American Diabetes Association. Pancreas transplantation for patients with type 1 diabetes. Diabetes Care 2000 23 : 117.
13. Hesse UJ, Troisi R, Jacobs B et al. A single center's clinical experience with quadruple immunosuppression including ATG or IL2 antibodies and mycophenolate mofetil in simultaneous pancreas-kidney transplants. Clin Transplant 2000 14 : 340 4.
14. Cantarovich D, Karam G, Giral-Classe M et al. Randomized comparison of triple therapy and antithymocyte globulin induction treatment after simultaneous pancreas-kidney transplantation. Kidney Int 1998 54 : 1351 6.
15. Mestre M, Bas J, Alsina J, Grinyo JM, Buendia E. Depleting effect of antithymocyte globulin on T-lymphocyte subsets in kidney transplantation. Transplant Proc 1999 31 : 2254 5.
16. Bourdage JS, Hamlin DM. Comparative polyclonal antithymocyte globulin and antilymphocyte/antilymphoblast globulin anti-CD antigen analysis by flow cytometry. Transplantation 1995 59 : 1194 200.
17. Wiseman LR, Faulds D. Daclizumab: a review of its use in the prevention of acute rejection in renal transplant recipients. Drugs 1999 58 : 1029 42.
18. Waldmann TA, O'Shea J. The use of antibodies against the IL-2 receptor in transplantation. Curr Opin Immunol 1998 10 : 507 12.
19. Vincenti F, Kirkman R, Light S et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. N Engl J Med 1998 338 : 161 5.
20. Nussenblatt RB, Fortin E, Schiffman R et al. Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial. Proc Natl Acad Sci USA 1999 96 : 7462 6.
21. Lo A, Stratta RJ, Alloway RR et al. Initial clinical experience with interleukin-2 receptor antagonist induction in combination with tacrolimus, mycophenolate mofetil and steroids in simultaneous kidney-pancreas transplantation. Transplant Int 2001 14 : 396 404.
22. Lehky TJ, Levin MC, Kubota R et al. Reduction in HTLV-I proviral load and spontaneous lymphoproliferation in HTLV-I-associated myelopathy/tropical spastic paraparesis patients treated with humanized anti-Tac. Ann Neurol 1998 44 : 942 7.
23. Bruce DS, Sollinger HW, Humar A et al. Multicenter survey of daclizumab induction in simultaneous kidney-pancreas transplant recipients. Transplantation 2001 72 : 1637 43.
24. Adu D, Cockwell P, Ives NJ, Shaw J, Wheatley K. Interleukin-2 receptor monoclonal antibodies in renal transplantation: meta-analysis of randomised trials. BMJ 2003 326 : 789.
25. Shapiro AM, Lakey JR, Ryan EA et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000 343 : 230 8.
26. Staeva-Vieira T, Peakman M, von Herrath M. Translational Mini-Review Series on Type 1 Diabetes. Immune-based therapeutic approaches for type 1 diabetes. Clin Exp Immunol 2007 148 : 17 31.
27. Kaden J, May G, Schonemann C et al. Effect of ATG prophylaxis in sensitized and non-sensitized kidney graft recipients. Transplant Int 1992 5 (Suppl. 1 S75 8.
28. Huurman VA, van de Kalpoe JS, LP et al. Choice of antibody immunotherapy influences cytomegalovirus viremia in simultaneous pancreas-kidney transplant recipients. Diabetes Care 2006 29 : 842 7.
29. van der Burg SH, de Cock K, Menon AG et al. Long lasting p53-specific T cell memory responses in the absence of anti-p53 antibodies in patients with resected primary colorectal cancer. Eur J Immunol 2001 31 : 146 55.
30. Chen W, Bergerot I, Elliott JF et al. Evidence that a peptide spanning the B-C junction of proinsulin is an early autoantigen epitope in the pathogenesis of type 1 diabetes. J Immunol 2001 167 : 4926 35.
31. Nabel GJ. Genetic, cellular and immune approaches to disease therapy. past and future. Nat Med 2004 10 : 135 41.
32. Herold KC, Hagopian W, Auger JA et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 2002 346 : 1692 8.
33. Muller TF, Grebe SO, Neumann MC et al. Persistent long-term changes in lymphocyte subsets induced by polyclonal antibodies. Transplantation 1997 64 : 1432 7.
34. Martins L, Ventura A, Dias L, Henriques A, Sarmento A, Guimaraes S. Long-term effects of ATG therapy on lymphocyte subsets. Transplant Proc 2001 33 : 2186 7.
35. Lange H, Muller TF, Ebel H et al. Immediate and long-term results of ATG induction therapy for delayed graft function compared to conventional therapy for immediate graft function. Transplant Int 1999 12 : 2 9.
36. Zwaveling S, Vierboom MP, Ferreira Mota SC et al. Antitumor efficacy of wild-type p53-specific CD4(+) T-helper cells. Cancer Res 2002 62 : 6187 93.
37. Palmer JP, Fleming GA, Greenbaum CJ et al. C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001. Diabetes 2004 53 : 250 64.
38. Jaeger C, Brendel MD, Hering BJ, Eckhard M, Bretzel RG. Progressive islet graft failure occurs significantly earlier in autoantibody-positive than in autoantibody-negative IDDM recipients of intrahepatic islet allografts. Diabetes 1997 46 : 1907 10.
39. Bosi E, Braghi S, Maffi P et al. Autoantibody response to islet transplantation in type 1 diabetes. Diabetes 2001 50 : 2464 71.